Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease

Detalhes bibliográficos
Autor(a) principal: Souza,Isabella D. P.
Data de Publicação: 2021
Outros Autores: Rodrigues,Kathryna F., Pietrani,Nathália T., Bosco,Adriana A., Gomes,Karina B., Alves,Michelle T.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442021000100400
Resumo: ABSTRACT INTRODUCTION: Type 2 diabetes mellitus (T2DM) is the most common manifestation of diabetes, accounting for about 90% of diagnosed cases. The causes of T2DM are not fully understood, but its pathogenesis is possibly associated with increased adiposity and a chronic low-grade inflammatory response. The glycoprotein galectin-3 (Gal-3) is known to play an important role in the modulation of blood glucose, adiposity, and inflammation. OBJECTIVES: The aim of this study was to evaluate Gal-3 levels in patients with T2DM and chronic kidney disease (CKD), in addition to relating them with complications and comorbidities present in these patients, comparing them to a control group. MATERIAL AND METHODS: Gal-3 was evaluated in 84 selected individuals, of which 42 had clinical and laboratory diagnosis of T2DM and CKD (treated at Santa Casa Hospital in Belo Horizonte, Minas Gerais, Brazil), and 42 individuals from the local community, with no history of diabetes (control group). RESULTS AND DISCURSION: Gal-3 levels were significantly higher (p = 0.012) in the T2DM group (15.17 ± 5.54 ng/ml) when compared to the control group (12.62 ± 3.2 ng/ml). There was a tendency for higher levels of Gal-3 in diabetic patients with hypertension (15.74 ± 5.61 ng/ml) when compared to patients without this complication (10.96 ± 2.49 ng/ml) (p = 0.069) CONCLUSION: The results suggest that Gal-3 may be involved in the pathophysiology of T2DM and still be a promising biomarker associated with hypertension in this group.
id SBP-1_f2fed86f24b97a31204f30df993e7b9d
oai_identifier_str oai:scielo:S1676-24442021000100400
network_acronym_str SBP-1
network_name_str Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
repository_id_str
spelling Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney diseasegalectin-3type 2 diabetes mellitusinflammationhypertensionABSTRACT INTRODUCTION: Type 2 diabetes mellitus (T2DM) is the most common manifestation of diabetes, accounting for about 90% of diagnosed cases. The causes of T2DM are not fully understood, but its pathogenesis is possibly associated with increased adiposity and a chronic low-grade inflammatory response. The glycoprotein galectin-3 (Gal-3) is known to play an important role in the modulation of blood glucose, adiposity, and inflammation. OBJECTIVES: The aim of this study was to evaluate Gal-3 levels in patients with T2DM and chronic kidney disease (CKD), in addition to relating them with complications and comorbidities present in these patients, comparing them to a control group. MATERIAL AND METHODS: Gal-3 was evaluated in 84 selected individuals, of which 42 had clinical and laboratory diagnosis of T2DM and CKD (treated at Santa Casa Hospital in Belo Horizonte, Minas Gerais, Brazil), and 42 individuals from the local community, with no history of diabetes (control group). RESULTS AND DISCURSION: Gal-3 levels were significantly higher (p = 0.012) in the T2DM group (15.17 ± 5.54 ng/ml) when compared to the control group (12.62 ± 3.2 ng/ml). There was a tendency for higher levels of Gal-3 in diabetic patients with hypertension (15.74 ± 5.61 ng/ml) when compared to patients without this complication (10.96 ± 2.49 ng/ml) (p = 0.069) CONCLUSION: The results suggest that Gal-3 may be involved in the pathophysiology of T2DM and still be a promising biomarker associated with hypertension in this group.Sociedade Brasileira de Patologia Clínica2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442021000100400Jornal Brasileiro de Patologia e Medicina Laboratorial v.57 2021reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)instname:Sociedade Brasileira de Patologia (SBP)instacron:SBP10.5935/1676-2444.20210010info:eu-repo/semantics/openAccessSouza,Isabella D. P.Rodrigues,Kathryna F.Pietrani,Nathália T.Bosco,Adriana A.Gomes,Karina B.Alves,Michelle T.eng2021-02-10T00:00:00Zoai:scielo:S1676-24442021000100400Revistahttp://www.scielo.br/jbpmlhttps://old.scielo.br/oai/scielo-oai.php||jbpml@sbpc.org.br1678-47741676-2444opendoar:2021-02-10T00:00Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)false
dc.title.none.fl_str_mv Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
title Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
spellingShingle Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
Souza,Isabella D. P.
galectin-3
type 2 diabetes mellitus
inflammation
hypertension
title_short Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
title_full Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
title_fullStr Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
title_full_unstemmed Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
title_sort Evaluation of galectin-3 levels in patients with type 2 diabetes mellitus and chronic kidney disease
author Souza,Isabella D. P.
author_facet Souza,Isabella D. P.
Rodrigues,Kathryna F.
Pietrani,Nathália T.
Bosco,Adriana A.
Gomes,Karina B.
Alves,Michelle T.
author_role author
author2 Rodrigues,Kathryna F.
Pietrani,Nathália T.
Bosco,Adriana A.
Gomes,Karina B.
Alves,Michelle T.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Souza,Isabella D. P.
Rodrigues,Kathryna F.
Pietrani,Nathália T.
Bosco,Adriana A.
Gomes,Karina B.
Alves,Michelle T.
dc.subject.por.fl_str_mv galectin-3
type 2 diabetes mellitus
inflammation
hypertension
topic galectin-3
type 2 diabetes mellitus
inflammation
hypertension
description ABSTRACT INTRODUCTION: Type 2 diabetes mellitus (T2DM) is the most common manifestation of diabetes, accounting for about 90% of diagnosed cases. The causes of T2DM are not fully understood, but its pathogenesis is possibly associated with increased adiposity and a chronic low-grade inflammatory response. The glycoprotein galectin-3 (Gal-3) is known to play an important role in the modulation of blood glucose, adiposity, and inflammation. OBJECTIVES: The aim of this study was to evaluate Gal-3 levels in patients with T2DM and chronic kidney disease (CKD), in addition to relating them with complications and comorbidities present in these patients, comparing them to a control group. MATERIAL AND METHODS: Gal-3 was evaluated in 84 selected individuals, of which 42 had clinical and laboratory diagnosis of T2DM and CKD (treated at Santa Casa Hospital in Belo Horizonte, Minas Gerais, Brazil), and 42 individuals from the local community, with no history of diabetes (control group). RESULTS AND DISCURSION: Gal-3 levels were significantly higher (p = 0.012) in the T2DM group (15.17 ± 5.54 ng/ml) when compared to the control group (12.62 ± 3.2 ng/ml). There was a tendency for higher levels of Gal-3 in diabetic patients with hypertension (15.74 ± 5.61 ng/ml) when compared to patients without this complication (10.96 ± 2.49 ng/ml) (p = 0.069) CONCLUSION: The results suggest that Gal-3 may be involved in the pathophysiology of T2DM and still be a promising biomarker associated with hypertension in this group.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442021000100400
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442021000100400
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/1676-2444.20210010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv
Sociedade Brasileira de Patologia Clínica
publisher.none.fl_str_mv
Sociedade Brasileira de Patologia Clínica
dc.source.none.fl_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial v.57 2021
reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
instname:Sociedade Brasileira de Patologia (SBP)
instacron:SBP
instname_str Sociedade Brasileira de Patologia (SBP)
instacron_str SBP
institution SBP
reponame_str Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
collection Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
repository.name.fl_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)
repository.mail.fl_str_mv ||jbpml@sbpc.org.br
_version_ 1752122297708183552